Published in Eur J Neurol on November 01, 2006
Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology (2010) 2.29
Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology (2014) 1.45
Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practice. J Neurol (2009) 1.06
Pains in Parkinson disease--many syndromes under one umbrella. Nat Rev Neurol (2012) 1.01
Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep (2008) 0.94
Factors associated with exercise behavior in people with Parkinson disease. Phys Ther (2011) 0.94
Move for change part I: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's disease. Eur J Neurol (2011) 0.91
Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.88
Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J Neural Transm (Vienna) (2013) 0.84
Targeting the progression of Parkinson's disease. Curr Neuropharmacol (2009) 0.82
The effects of a mindfulness-based lifestyle programme for adults with Parkinson's disease: protocol for a mixed methods, randomised two-group control study. BMJ Open (2013) 0.81
Effects of home exercise on physical function and activity in home care patients with Parkinson's disease. J Phys Ther Sci (2014) 0.81
Deep Brain Stimulation Can Preserve Working Status in Parkinson's Disease. Parkinsons Dis (2015) 0.81
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients. Neuropsychiatr Dis Treat (2011) 0.80
MR-guided focused ultrasound: a new generation treatment of Parkinson's disease, essential tremor and neuropathic pain. Interv Neuroradiol (2014) 0.79
Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis. PLoS One (2016) 0.78
Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis. Appl Health Econ Health Policy (2013) 0.78
Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease. Curr Neuropharmacol (2016) 0.78
A review of ropinirole prolonged release in Parkinson's disease. Clin Interv Aging (2009) 0.77
The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease. Transl Neurodegener (2016) 0.77
Pharmacotherapy in Parkinson's disease: case studies. Ther Adv Neurol Disord (2010) 0.76
The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study. Eur J Med Res (2013) 0.75
A Kinect-Based Physiotherapy and Assessment Platform for Parkinson's Disease Patients. J Med Eng (2016) 0.75
Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexole. Patient Prefer Adherence (2012) 0.75
Gastrointestinal Dysfunctions in Parkinson's Disease: Symptoms and Treatments. Parkinsons Dis (2016) 0.75
The impact of early versus late levodopa administration. J Neural Transm (Vienna) (2016) 0.75
The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease. J Neurol (2014) 0.75
Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease. J Neurol (2011) 0.75
Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson's Disease Differently Affects Behavior. Front Behav Neurosci (2017) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 10.14
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
T cell-independent antigens type 2. Annu Rev Immunol (1995) 4.62
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol (2010) 4.55
Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol (1994) 4.07
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology (2010) 4.06
Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology (2008) 3.68
Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature (1998) 3.46
EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol (2005) 3.17
Genomic instability in Gadd45a-deficient mice. Nat Genet (1999) 3.01
EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol (2010) 2.92
Persistent calcium elevation correlates with the induction of surface immunoglobulin-mediated B cell DNA synthesis. J Exp Med (1993) 2.88
EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol (2006) 2.86
Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation (2001) 2.82
Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol (2010) 2.77
Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology (2005) 2.69
Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ (1999) 2.66
Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med (1995) 2.58
Environmental risk factors for REM sleep behavior disorder: a multicenter case-control study. Neurology (2012) 2.54
Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J Exp Med (1992) 2.47
Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study) BMJ (1996) 2.42
EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol (2009) 2.39
Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc (2000) 2.38
Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry (2002) 2.36
EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol (2009) 2.31
White matter hyperintensities in Parkinson's disease. Clinical correlations. Arch Neurol (1995) 2.30
Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. J Neurosurg (2001) 2.27
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (1999) 2.23
Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation (1997) 2.18
Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology (2006) 2.17
B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev (2000) 2.17
Ictal laughter associated with paroxysmal hypothalamopituitary dysfunction. Epilepsia (1997) 2.14
Slow inactivation of Na+ current and slow cumulative spike adaptation in mouse and guinea-pig neocortical neurones in slices. J Physiol (1996) 2.07
Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (1999) 2.07
Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol (1996) 2.06
Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology (2001) 2.06
Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease. Arch Neurol (2001) 2.06
Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain (2000) 2.06
T lymphocyte line specific for thyroglobulin produces or vaccinates against autoimmune thyroiditis in mice. J Immunol (1983) 2.05
Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol (1993) 2.05
Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol (2010) 2.03
Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease. J Neurol Neurosurg Psychiatry (2001) 1.98
Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol (2001) 1.97
Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry (1999) 1.95
The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol (1996) 1.94
Subacute combined degeneration: clinical, electrophysiological, and magnetic resonance imaging findings. J Neurol Neurosurg Psychiatry (1998) 1.94
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord (1987) 1.92
Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev (2003) 1.91
Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem (1992) 1.91
The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry (2009) 1.89
Dementia and survival in Parkinson disease: a 12-year population study. Neurology (2008) 1.86
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology (2005) 1.86
Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology (1997) 1.85
Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol (2010) 1.85
Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology (2005) 1.85
Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol (1998) 1.82
Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin. Eur J Immunol (1993) 1.82
Foreign body in the airway. A review of 200 cases. Am J Dis Child (1980) 1.82
Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med (1997) 1.81
Psychiatric comorbidity in a population of Parkinson's disease patients. Eur J Neurol (2004) 1.80
T cell independent antigens. Curr Opin Immunol (1995) 1.78
Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology (2005) 1.77
Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J Neuropathol Exp Neurol (2004) 1.76
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
Juvenile asymmetric segmental spinal muscular atrophy (Hirayama's disease): three cases without evidence of "flexion myelopathy". Acta Neurol Scand (2001) 1.74
Blood-brain barrier disruption results in delayed functional and structural alterations in the rat neocortex. Neurobiol Dis (2006) 1.73
EFNS guideline on mild traumatic brain injury: report of an EFNS task force. Eur J Neurol (2002) 1.73
Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes. Lancet (1989) 1.72
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol (1988) 1.72
A rapid infusion protocol is safe for total dose iron polymaltose: time for change. Intern Med J (2011) 1.70
Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry (2000) 1.70
EFNS guideline on the management of status epilepticus in adults. Eur J Neurol (2009) 1.69
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry (1998) 1.69
Isolation and characterization of the minimal fragment required for autonomous replication ("basic replicon") of a copy mutant (pKN102) of the antibiotic resistance factor R1. Mol Gen Genet (1978) 1.68
Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology (1999) 1.67
The role of the CCAAT/enhancer-binding protein in the transcriptional regulation of the gene for phosphoenolpyruvate carboxykinase (GTP). Mol Cell Biol (1990) 1.67
Regenerative activity in apical dendrites of pyramidal cells in neocortex. Cereb Cortex (1993) 1.66
Task-related changes in the effect of magnetic brain stimulation on spinal neurones in man. J Physiol (1993) 1.65
Delayed hypersensitivity in Graves' disease and exophthalmos: identification of thyroglobulin in normal human orbital muscle. Endocrinology (1977) 1.64
Galloway-Mowat syndrome of abnormal gyral patterns and glomerulopathy. Am J Med Genet (1993) 1.64
The delayed-start study in Parkinson disease: can't satisfy everyone. Neurology (2010) 1.63
A synthetic gene coding for the green fluorescent protein (GFP) is a versatile reporter in Chlamydomonas reinhardtii. Plant J (1999) 1.62
Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry (2000) 1.62
Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov Disord (2001) 1.61
A new approach to the sequence analysis of DNA. FEBS Lett (1972) 1.60
IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology (2003) 1.60
Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology (2011) 1.59